tegafur has been researched along with Adverse Drug Event in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Overall health-related quality of life did not deteriorate during adjuvant chemotherapy with oral uracil/tegafur plus leucovorin in patients with colorectal cancer, despite the effect from surgical damage, whereas the development of Grade 3 toxicities negatively affected on short-term health-related quality of life." | 7.76 | Health-related quality of life in patients with colorectal cancer who receive oral uracil and tegafur plus leucovorin. ( Matsui, N; Nakao, K; Tsunoda, A; Tsunoda, Y; Watanabe, M, 2010) |
| "Hyperammonemia cases were more likely to be reported with intravenous fluorouracil than orally administered fluoropyrimidines." | 4.31 | Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database. ( Agatsuma, N; Imamaki, H; Nishikawa, Y; Oguro, F; Oura, M, 2023) |
| "5 mg/d) and S-1 (100 mg/d), a combination preparation of tegafur, gimeracil, and oteracil potassium, to treat cholangiocarcinoma." | 3.81 | A Successful Case of a Patient Undergoing Warfarin and S-1 Therapy Using Internet-based Control of Home-measured PT-INR. ( Hirashiki, A; Hirooka, Y; Murohara, T; Yamada, K; Yamamura, K; Yano, K, 2015) |
| "Overall health-related quality of life did not deteriorate during adjuvant chemotherapy with oral uracil/tegafur plus leucovorin in patients with colorectal cancer, despite the effect from surgical damage, whereas the development of Grade 3 toxicities negatively affected on short-term health-related quality of life." | 3.76 | Health-related quality of life in patients with colorectal cancer who receive oral uracil and tegafur plus leucovorin. ( Matsui, N; Nakao, K; Tsunoda, A; Tsunoda, Y; Watanabe, M, 2010) |
| "Patients aged 20-80 with stage II/III rectal cancer undergoing curative surgery without preoperative therapy were randomly assigned to receive UFT (500-600 mg/day on days 1-5, followed by 2 days rest) or S-1 (80-120 mg/day on days 1-28, followed by 14 days rest) for 1 year." | 2.82 | A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC). ( Baba, H; Emi, Y; Hamada, C; Ikejiri, K; Kakeji, Y; Kotake, M; Maeda, K; Maehara, Y; Matsuda, C; Matsuda, H; Munemoto, Y; Murata, A; Oki, E; Saji, S; Sasaki, K; Suenaga, T; Yoshida, K, 2016) |
| "Nutritional therapy is used to reduce the adverse events (AEs) of anticancer drugs." | 2.82 | Oral administration of the amino acids cystine and theanine attenuates the adverse events of S-1 adjuvant chemotherapy in gastrointestinal cancer patients. ( Hashimoto, T; Honda, H; Kakita, T; Kayahara, T; Kurihara, S; Oikawa, M; Oishi, H; Oyama, A; Shibakusa, T; Tochikubo, K; Tsuchiya, T, 2016) |
| " S-1 was shown to be effective and safe in Japanese metastatic breast cancer patients treated with previous chemotherapy, including anthracyclines." | 1.42 | Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study. ( Hirokawa, E; Kanbayashi, C; Nakamiya, N; Osaki, A; Saeki, T; Sano, H; Sato, N; Sekine, H; Shigekawa, T; Shimada, H; Sugitani, I; Sugiyama, M; Takahashi, T; Takeuchi, H; Ueda, S, 2015) |
| " We examined 1361 patients between January 2006 and December 2007 with regard to the incidence of adverse drug reactions graded by the Common Terminology Criteria for Adverse Events (CTCAE), version 3." | 1.37 | Post-marketing safety evaluation of S-1 in patients with inoperable or recurrent breast cancer: especially in patients treated with S-1 + trastuzumab. ( Okamura, T; Oshitanai, R; Saito, Y; Suzuki, Y; Terada, M; Terao, M; Tokuda, Y; Tsuda, B, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (93.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Oura, M | 1 |
| Oguro, F | 1 |
| Agatsuma, N | 1 |
| Imamaki, H | 1 |
| Nishikawa, Y | 1 |
| Cho, JH | 1 |
| Lim, JY | 1 |
| Cho, JY | 1 |
| Chou, WC | 1 |
| Chang, CL | 1 |
| Liu, KH | 1 |
| Hsu, JT | 1 |
| Cheng, WH | 1 |
| Hsu, HC | 1 |
| Shen, WC | 1 |
| Hung, YS | 1 |
| Chen, JS | 1 |
| Zhang, E | 1 |
| Cao, W | 1 |
| Cheng, C | 1 |
| Huo, BL | 1 |
| Wang, YH | 1 |
| Komura, T | 1 |
| Miura, K | 1 |
| Shirasaka, T | 1 |
| Ohnuma, S | 1 |
| Shimada, M | 1 |
| Kajiwara, T | 1 |
| Fujishima, F | 1 |
| Philchenkov, A | 1 |
| Nakagawa, K | 2 |
| Kudoh, K | 1 |
| Haneda, S | 1 |
| Toshima, M | 1 |
| Kohyama, A | 1 |
| Musha, H | 1 |
| Naitoh, T | 1 |
| Shibata, C | 1 |
| Unno, M | 1 |
| Naito, T | 1 |
| Seto, T | 1 |
| Takeda, K | 1 |
| Goto, K | 1 |
| Okamoto, I | 1 |
| Ohba, T | 1 |
| Murakami, H | 1 |
| Takahashi, T | 3 |
| Yamanaka, T | 1 |
| Yamamoto, N | 1 |
| Kurokawa, Y | 1 |
| Hamakawa, T | 1 |
| Miyazaki, Y | 1 |
| Yamasaki, M | 1 |
| Miyata, H | 1 |
| Nakajima, K | 1 |
| Takiguchi, S | 1 |
| Mori, M | 1 |
| Doki, Y | 1 |
| Shigekawa, T | 1 |
| Osaki, A | 1 |
| Sekine, H | 1 |
| Sato, N | 1 |
| Kanbayashi, C | 1 |
| Sano, H | 1 |
| Takeuchi, H | 1 |
| Ueda, S | 1 |
| Nakamiya, N | 1 |
| Sugitani, I | 1 |
| Sugiyama, M | 1 |
| Shimada, H | 1 |
| Hirokawa, E | 1 |
| Saeki, T | 1 |
| Yamamura, K | 1 |
| Yano, K | 1 |
| Hirooka, Y | 1 |
| Hirashiki, A | 1 |
| Murohara, T | 1 |
| Yamada, K | 1 |
| Oki, E | 1 |
| Murata, A | 1 |
| Yoshida, K | 1 |
| Maeda, K | 1 |
| Ikejiri, K | 1 |
| Munemoto, Y | 1 |
| Sasaki, K | 1 |
| Matsuda, C | 1 |
| Kotake, M | 1 |
| Suenaga, T | 1 |
| Matsuda, H | 1 |
| Emi, Y | 1 |
| Kakeji, Y | 1 |
| Baba, H | 1 |
| Hamada, C | 1 |
| Saji, S | 1 |
| Maehara, Y | 1 |
| Tsuchiya, T | 1 |
| Honda, H | 1 |
| Oikawa, M | 1 |
| Kakita, T | 1 |
| Oyama, A | 1 |
| Oishi, H | 1 |
| Tochikubo, K | 1 |
| Hashimoto, T | 1 |
| Kurihara, S | 1 |
| Shibakusa, T | 1 |
| Kayahara, T | 1 |
| Tsunoda, A | 1 |
| Nakao, K | 1 |
| Watanabe, M | 1 |
| Matsui, N | 1 |
| Tsunoda, Y | 1 |
| Hatano, K | 1 |
| Nonomura, N | 1 |
| Nishimura, K | 1 |
| Kawashima, A | 1 |
| Mukai, M | 1 |
| Nagahara, A | 1 |
| Nakai, Y | 1 |
| Nakayama, M | 1 |
| Takayama, H | 1 |
| Tsujimura, A | 1 |
| Okuyama, A | 1 |
| Saito, Y | 1 |
| Oshitanai, R | 1 |
| Terao, M | 1 |
| Terada, M | 1 |
| Tsuda, B | 1 |
| Okamura, T | 1 |
| Suzuki, Y | 1 |
| Tokuda, Y | 1 |
| Yokota, T | 1 |
| Onozawa, Y | 1 |
| Boku, N | 1 |
| Hamauchi, S | 1 |
| Tsushima, T | 1 |
| Taniguchi, H | 1 |
| Todaka, A | 1 |
| Machida, N | 1 |
| Yamazaki, K | 1 |
| Fukutomi, A | 1 |
| Yasui, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for tegafur and Adverse Drug Event
| Article | Year |
|---|---|
Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combi | 2014 |
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2016 |
Oral administration of the amino acids cystine and theanine attenuates the adverse events of S-1 adjuvant chemotherapy in gastrointestinal cancer patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cystine; | 2016 |
13 other studies available for tegafur and Adverse Drug Event
| Article | Year |
|---|---|
Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database.
Topics: Antimetabolites; Antineoplastic Agents; Capecitabine; Drug-Related Side Effects and Adverse Reaction | 2023 |
Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, | 2017 |
Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Mo | 2013 |
A systemic analysis of S-1 regimens for treatment of patients with colon cancer.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2014 |
Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2015 |
News products to avoid.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Azacitidine; Decita | 2014 |
Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer.
Topics: Adult; Aged; Cisplatin; Docetaxel; Drug Combinations; Drug-Related Side Effects and Adverse Reaction | 2015 |
Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.
Topics: Adult; Aged; Anthracyclines; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Combinations; Drug-Relat | 2015 |
A Successful Case of a Patient Undergoing Warfarin and S-1 Therapy Using Internet-based Control of Home-measured PT-INR.
Topics: Cholangiocarcinoma; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Drug-Related Si | 2015 |
Health-related quality of life in patients with colorectal cancer who receive oral uracil and tegafur plus leucovorin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined | 2010 |
Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide for hormone-refractory prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combi | 2011 |
Post-marketing safety evaluation of S-1 in patients with inoperable or recurrent breast cancer: especially in patients treated with S-1 + trastuzumab.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antine | 2011 |
S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Disease-Free Survival; Drug | 2011 |